InterCure Ltd. (INCR)
Valuation Overview•Is InterCure Ltd. Overvalued or Undervalued?
Trading at a relative discount to industry peers, suggesting a specific risk premium is applied.
Fragile underlying quality score of 18/100; weak margins or elevated debt leverage warrant caution.
Wall Street forecasts a balanced outlook with consensus price targets near the current price.
Verdict: Highly distressed profile flashing severe fundamental warning signs.
Wall Street sentiment is generally neutral. The company currently dilutes shareholders to fund operations and growth rather than returning capital.
INCR struggles with subpar profitability and pressured margins. This is paired with a moderately leveraged but stable balance sheet.
The company exhibits steady, low-single-digit revenue growth paired with stable bottom-line earnings. However, profitability remains a major concern with severely compressed operating margins (-29.6%).
| Financial Metric | Trend (12Q) | Latest Qtr | 1Y Growth | 3Y CAGR | 5Y CAGR | 10Y CAGR |
|---|---|---|---|---|---|---|
| Revenue | $65.0M | -32.8% | +2.8% | +93.0% | +45.4% | |
| EBITDA | $7.1M | — | — | — | — | |
| Net Income | -$852K | -9.4% | — | — | -33.4% | |
| EPS (Diluted) | $-0.01 | -4.4% | — | — | +4.9% | |
| Free Cash Flow | $4.5M | -26.8% | — | -77.8% | — |
| Metric | TTM | 3Y Avg | 5Y Avg | 10Y Avg |
|---|---|---|---|---|
| Gross Margin | 16.7% | 27.4% | 34.6% | 35.8% |
| Operating Margin | -29.6% | -8.9% | -14.6% | -41.5% |
| Net Margin | -29.2% | -11.4% | -17.9% | -41.4% |
| FCF Margin | 3.7% | -12.5% | -10.5% | -31.2% |
Total return is -33.8% (1Y), lagging the benchmark by -54.6%
| Period | Total Return | vs S&P 500 (Alpha) | Dividend Contribution |
|---|---|---|---|
| YTD | -2.9% | -10.2% | — |
| 1Y | -33.8% | -54.6% | — |
| 3YCAGR | -18.4% | -36.5% | — |
| 5YCAGR | -32.6% | -43.1% | — |
| 10YCAGR | -11.5% | -24.5% | — |
The S&P 500 is at 30.6x trailing P/E — Expensive relative to historical averages.
Quick answers to common questions about InterCure Ltd. (INCR) valuation, health, and returns.
Based on peer relative multiples, InterCure Ltd. appears Limited: Cheap versus peers compared to industry peers.
InterCure Ltd. has multiple valuation anchors: Peer Relative Fair Value: $2.93. A convergence of these signals offers higher conviction.
InterCure Ltd. displays poor financial health with a composite quality score of 18/100, supported by a Altman Z-Score of -0.3 (distress zone), Piotroski F-Score of 1/9, Return on Invested Capital (ROIC) of -9.3%.
InterCure Ltd. does not return material capital to shareholders via dividends or share repurchases, electing to retain earnings to fund internal growth.
InterCure Ltd.'s current growth trajectory is Decelerating. The company achieved -32.8% 1Y revenue growth and -4.4% 1Y EPS growth, compared to its 3Y revenue CAGR of +2.8%.
Wall Street consensus is Hold based on 0 analysts. The consensus price target represents a N/A change from current levels.
Investment risks for InterCure Ltd. include: -57.8% 1-year max drawdown, elevated distress risk. Volatility risk is characterized by a beta of 0.91x.
No. These computations are purely quantitative model outputs for informational purposes. They do not account for qualitative management shifts or macro events. Always consult a licensed RIA before buying or selling shares.
Disclaimer: This page is for informational purposes only and does not constitute financial advice. All valuation models, scores, and target estimates are automated computations under stated assumptions and should not be relied upon as the sole basis for any investment decision.